FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283700713> ?p ?o ?g. }

• W4283700713 endingPage "1687" @default.
• W4283700713 startingPage "1686.2" @default.
• W4283700713 abstract "Background Patients (pts) with autoimmune diseases are at higher risk of infections, including those by SARS-COV-2. There is no general agreement regarding priority criteria for anti-COVID vaccine access for pts with autoimmune rheumatic diseases (ARD). Few studies have addressed the issue of anti-COVID vaccination in these pts, but many are available on the safety, immunogenicity, efficacy, and possible contraindications of traditional vaccines in pts with ARD. These studies may represent the basis on which to recommend the anti-COVID-19 vaccines. Objectives Patients (pts) with autoimmune diseases are at higher risk of infections, including those by SARS-COV-2. There is no general agreement regarding priority criteria for anti-COVID vaccine access for pts with autoimmune rheumatic diseases (ARD). Few studies have addressed the issue of anti-COVID vaccination in these pts, but many are available on the safety, immunogenicity, efficacy, and possible contraindications of traditional vaccines in pts with ARD. These studies may represent the basis on which to recommend the anti-COVID-19 vaccines. Methods A telephone survey investigating the AE of SARS-CoV-2 vaccinations on pts with systemic lupus erythematosus, systemic sclerosis, inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis), idiopathic inflammatory myopathies, ANCA-associated vasculitis was administered. Data extraction included diagnosis, disease activity status, demographics, disease duration, therapy, comorbidities, and laboratory tests. Vaccinated participants are asked to report whether they experienced any local or systemic AE following vaccination, and if so, to report on the severity and duration of the AE. Mild AE were defined as unpleasant reactions that did not limit daily activities, moderate AE as those that limited daily activities, and severe AE - required medical attention. Serious AE were defined as reactions that resulted in hospital admission. Results ChAdOx1 nCoV-19 and BNT162b2 are the most common vaccines in our pts. 98 (39,84 %) of 246 pts received the BNT162b2 vaccine, 95 (38,62 %) - ChAdOx1 nCoV-19 vaccine, 47 (19,10%) - CX-024414 and 6 (2,44 %) were vaccinated with Ad26.COV2-S. 127 (51,63%) pts had at least one mild AE and 51 (20,73 %) pts reported moderate AE. Severe AE were rare - 4 (1,63 %) pts and no serious AE were reported. The most commonly reported AE is pain (40,24 %), redness (30,49 %), swelling (18,7 %) at the injection site, which was consistent across all vaccines for both first and second doses. Systemic AE occurred in 104 (43,27 %) pts, most frequently fatigue (29,67 %), headache (27,13 %) and muscle ache (24,39 %). The symptoms started mostly during the first day post-vaccination and lasted for no more than two days. Joint complaints were reported in 8,94 %, but only a small proportion of pts (2,84 %) reported a deterioration of their autoimmune disease up to 3 months after COVID-19 vaccination. Age was a significant effect modifier in the association between autoimmune status and the risk of moderate or severe AE. Vaccination with ChAdOx1 nCoV-19, female sex, age between 35 - 50 years were independently associated with an increased likelihood of reporting any AE. The current results support the safety of different COVID-19 vaccines in pts with ARD. This information can help fight vaccine hesitancy in this population. Conclusion Our data indicated that COVID-19 vaccines are well tolerated by pts with ARD. We did not observe any serious AE, but the number of pts included in our study is too low to draw conclusions about rare serious events. Additionally, our data suggest that COVID-19 vaccinations do not seem to trigger autoimmune disease flares, which is in accordance with data from previous small studies that assessed consequences of vaccines in pts with ARD. Disclosure of Interests None declared" @default.
• W4283700713 created "2022-06-30" @default.
• W4283700713 creator A5016611722 @default.
• W4283700713 creator A5055964580 @default.
• W4283700713 creator A5085005958 @default.
• W4283700713 date "2022-05-23" @default.
• W4283700713 modified "2023-09-27" @default.
• W4283700713 title "AB1138 SAFETY OF SARS - COV- 2 VACCINES IN PATIENTS WITH AUTOIMMUNE DISEASES" @default.
• W4283700713 doi "https://doi.org/10.1136/annrheumdis-2022-eular.3462" @default.
• W4283700713 hasPublicationYear "2022" @default.
• W4283700713 type Work @default.
• W4283700713 citedByCount "1" @default.
• W4283700713 countsByYear W42837007132023 @default.
• W4283700713 crossrefType "journal-article" @default.
• W4283700713 hasAuthorship W4283700713A5016611722 @default.
• W4283700713 hasAuthorship W4283700713A5055964580 @default.
• W4283700713 hasAuthorship W4283700713A5085005958 @default.
• W4283700713 hasBestOaLocation W42837007131 @default.
• W4283700713 hasConcept C126322002 @default.
• W4283700713 hasConcept C159654299 @default.
• W4283700713 hasConcept C203014093 @default.
• W4283700713 hasConcept C22070199 @default.
• W4283700713 hasConcept C2776260265 @default.
• W4283700713 hasConcept C2777077863 @default.
• W4283700713 hasConcept C2777402515 @default.
• W4283700713 hasConcept C2777575956 @default.
• W4283700713 hasConcept C2779134260 @default.
• W4283700713 hasConcept C2780868878 @default.
• W4283700713 hasConcept C71924100 @default.
• W4283700713 hasConceptScore W4283700713C126322002 @default.
• W4283700713 hasConceptScore W4283700713C159654299 @default.
• W4283700713 hasConceptScore W4283700713C203014093 @default.
• W4283700713 hasConceptScore W4283700713C22070199 @default.
• W4283700713 hasConceptScore W4283700713C2776260265 @default.
• W4283700713 hasConceptScore W4283700713C2777077863 @default.
• W4283700713 hasConceptScore W4283700713C2777402515 @default.
• W4283700713 hasConceptScore W4283700713C2777575956 @default.
• W4283700713 hasConceptScore W4283700713C2779134260 @default.
• W4283700713 hasConceptScore W4283700713C2780868878 @default.
• W4283700713 hasConceptScore W4283700713C71924100 @default.
• W4283700713 hasIssue "Suppl 1" @default.
• W4283700713 hasLocation W42837007131 @default.
• W4283700713 hasOpenAccess W4283700713 @default.
• W4283700713 hasPrimaryLocation W42837007131 @default.
• W4283700713 hasRelatedWork W145086642 @default.
• W4283700713 hasRelatedWork W1997363697 @default.
• W4283700713 hasRelatedWork W1997953917 @default.
• W4283700713 hasRelatedWork W2040982081 @default.
• W4283700713 hasRelatedWork W2116174976 @default.
• W4283700713 hasRelatedWork W2182099883 @default.
• W4283700713 hasRelatedWork W2369623981 @default.
• W4283700713 hasRelatedWork W2743764001 @default.
• W4283700713 hasRelatedWork W3007410422 @default.
• W4283700713 hasRelatedWork W4242931419 @default.
• W4283700713 hasVolume "81" @default.
• W4283700713 isParatext "false" @default.
• W4283700713 isRetracted "false" @default.
• W4283700713 workType "article" @default.